Continuing Education Activity

Cholinesterase inhibitors are widely used to manage cognitive symptoms in Alzheimer disease and related dementias, as well as in select neurological and perioperative settings. This activity provides a comprehensive, evidence-based review of their clinical use, covering indications, contraindications, mechanisms of action, adverse effect profiles, dosing strategies, monitoring parameters, off-label applications, and clinically significant drug interactions. This activity also emphasizes strategies to minimize adverse effects while maximizing the therapeutic effectiveness of cholinesterase inhibitors. Participants will gain practical guidance on tailoring therapy to individual patient characteristics, comorbidities, and treatment goals. The activity emphasizes evidence-based strategies for monitoring therapy, recognizing and managing adverse reactions, adjusting dosing regimens, preventing therapy-related complications, and optimizing both safety and therapeutic effectiveness to improve patient outcomes.

This activity highlights the essential role of the interprofessional healthcare team and equips them with evidence-based knowledge to deliver safe, individualized care when administering cholinesterase inhibitors to achieve optimal outcomes. Collaboration among physicians, advanced practice providers, nurses, and pharmacists is emphasized to support appropriate prescribing, patient education, and ongoing monitoring. By enhancing understanding of the pharmacology and clinical applications of cholinesterase inhibitors, the program promotes informed decision-making and patient-centered care. Overall, the CME activity aims to strengthen clinical competence, improve medication safety, and maximize treatment effectiveness, ultimately contributing to better patient outcomes through high-quality, evidence-based practice.

Objectives:

• Identify the indications, contraindications, and off-label uses of cholinesterase inhibitors in neurological, perioperative, and systemic conditions.
• Implement evidence-based dosing strategies and monitoring protocols for safe and effective administration.
• Select appropriate cholinesterase inhibitors and formulations based on patient-specific characteristics, comorbidities, and treatment goals.
• Collaborate with the interprofessional healthcare team to optimize therapeutic outcomes, minimize adverse effects, and ensure safe, individualized, and effective therapy.

Indications

Cholinesterase inhibitors, also known as acetylcholinesterase (AChE) inhibitors or anticholinesterases, are a group of drugs that block the normal breakdown of acetylcholine (ACh) into acetate and choline. By inhibiting this process, they increase both the levels and duration of action of ACh in the central and peripheral nervous systems.

The AChE inhibitors have a variety of indications, most commonly in the treatment of neurodegenerative diseases such as Alzheimer and Parkinson diseases, as well as Lewy body dementia.[1][2][3] In these degenerative disorders, various pathological processes destroy cells that produce ACh, thereby reducing cholinergic transmission in different regions of the brain. Cholinesterase inhibitors counteract this effect by inhibiting AChE activity and decreasing the rate of ACh breakdown, thereby maintaining ACh levels.[4] Furthermore, cholinesterase inhibitors are frequently used in patients with myasthenia gravis. By increasing ACh levels at the neuromuscular junction, these agents enhance activation of ACh receptors on the postsynaptic membrane, thereby improving muscle activation, contraction, and strength.

At the conclusion of surgery, cholinesterase inhibitors, most commonly neostigmine, are administered to reverse the effects of nondepolarizing muscle agents such as rocuronium.[5][6][7][8][9] Neostigmine is also used for the management of postoperative paralytic ileus and postoperative urinary retention.[10][11]

Cholinesterase inhibitors may also be indicated in cases when anticholinergic poisoning is suspected. Common symptoms of anticholinergic poisoning include vasodilation, anhidrosis, mydriasis, delirium, and urinary retention.[12][11]

Other less common indications of cholinesterase inhibitors include the treatment of patients diagnosed with certain psychiatric disorders, such as schizophrenia, and the management of glaucoma by relieving aqueous humor pressure.[13] In 2024, the US Food and Drug Administration (FDA) approved benzgalantamine (Zuventyl), a prodrug of galantamine, for the treatment of mild-to-moderate Alzheimer dementia.[14] 

The American Academy of Sleep Medicine suggests that clinicians use transdermal rivastigmine (compared with no treatment) for isolated rapid eye movement sleep behavior disorder in adults with mild cognitive impairment (off-label use; conditional recommendation).[15] Pyridostigmine is also used to treat neurogenic orthostatic hypotension by facilitating cholinergic neurotransmission in autonomic ganglia.[16][17]

AChE inhibitors are broadly classified into reversible- and irreversible-acting inhibitors. The table below summarizes FDA-approved drugs and their indications. Notably, agricultural pesticides and chemical warfare agents are considered toxins.

Table

Table 1. Classification of Acetylcholinesterase Inhibitors, FDA-Approved Drugs, and Clinical Indications.

Mechanism of Action

Cholinesterase inhibitors function by inhibiting cholinesterase from hydrolyzing ACh into acetate and choline, thereby increasing both the availability and duration of ACh action at neuromuscular junctions. The cholinesterase enzyme has 2 active sites: an anionic site (formed by tryptophan) and an esteractic site (formed by serine). Cholinesterase inhibitors, such as organophosphates, inhibit cholinesterase from cleaving ACh by interacting with the serine esteractic site. This leads to the accumulation of ACh and prolonged activation of its associated receptors.[19]

Cholinesterase inhibitors are classified as reversible, irreversible, or pseudo-reversible. Reversible cholinesterase inhibitors are generally utilized for therapeutic purposes. In contrast, irreversible and pseudo-reversible inhibitors are often used in pesticides and biowarfare (nerve agents).[20][21]

Pharmacokinetics

The general pharmacokinetic properties are summarized in the table below for better comprehension. Detailed pharmacokinetic information for each drug should be obtained from its product labeling.

Table

Table 2. Pharmacokinetic Properties of Selected Cholinesterase Inhibitors.

Abbreviations: BBB, blood-brain barrier; CNS, central nervous system; CYP, cytochrome P450; IV, intravenous.

Administration

Available Dosage Forms and Strengths

Cholinesterase inhibitors are available in multiple dosage forms and can be administered via intramuscular (IM), intravenous (IV), or oral routes, depending on the specific agent and clinical indication. The specific formulation and route of administration vary depending on the individual agent and its clinical use. For example, neostigmine is available as an injectable solution to counteract the effects of muscle relaxants at the end of surgery. In contrast, an oral form of neostigmine is available for the treatment of myasthenia gravis. Rivastigmine, commonly prescribed for patients with dementia, is available as a transdermal patch, which is also frequently used in clinical practice.[22][23]

Cholinesterase inhibitors are available in several formulations for both central nervous system and peripheral nervous system indications. Donepezil is available as film-coated tablets in strengths of 5 mg, 10 mg, and 23 mg. Galantamine is formulated as immediate-release tablets and extended-release capsules in strengths ranging from 4 mg to 24 mg. Benzgalantamin is available as delayed-release tablets in 5 mg, 10 mg, and 15 mg strengths. Rivastigmine is available as oral capsules (1.5 mg, 3 mg, 4.5 mg, and 6 mg) and as transdermal patch systems delivering 4.6 or 9.5 mg per 24 hours.[24] Pyridostigmine is available as 60 mg immediate-release tablets, 180 mg extended-release tablets, an oral solution (60 mg/5 mL), and parenteral formulations. Neostigmine is available as a sterile injectable solution in concentrations such as 0.5 mg/mL and 1 mg/mL. Physostigmine is available as an injectable solution, typically at 1 mg/mL, for IV or IM use, and is used exclusively for the management of anticholinergic toxicity.  

Adult Dosage

Adult dosing varies according to indication, disease severity, hepatic and renal impairment, and concomitant medications. 

• Donepezil is typically initiated at 5 mg once daily and titrated to 10 mg after several weeks, as tolerated. The 23 mg formulation is reserved for patients with moderate-to-severe Alzheimer disease who have demonstrated tolerance to 10 mg daily.

• Galantamine is initiated at the lowest tolerated dose and titrated every 4 weeks to achieve therapeutic targets. Extended-release formulations may allow once-daily administration up to 24 mg.

• Benzgalantamine follows a similar titration schedule as galantamine, with a starting dose of 10 mg daily (divided into 5-mg doses) and gradual escalation based on tolerability.

• Rivastigmine also requires slow titration, beginning with low doses of oral capsules administered twice daily or a 4.6 mg per 24 hours transdermal patch. The dose is increased after several weeks, as tolerated, to reach the target maintenance level. The maximum dose of the rivastigmine transdermal system is 13.3 mg per 24 hours once daily, and is used in patients with severe Alzheimer dementia.

• Pyridostigmine dosing for myasthenia gravis is individualized, typically using immediate-release tablets administered multiple times daily, with dose adjustments based on clinical response. The extended-release 180 mg formulation is administered once or twice daily, depending on clinical needs.

• Neostigmine is dosed by body weight to reverse nondepolarizing neuromuscular blockade. The drug is typically administered via the IV route at 0.03 to 0.07 mg/kg, slowly, with concurrent anticholinergic therapy to prevent muscarinic adverse effects.

• Physostigmine is used only for severe anticholinergic toxicity and is administered via the IV route with cautious, titrated dosing based on clinical response, due to its short half-life and risk of bradyarrhythmia and seizures.

Specific Patient Populations

The table below summarizes key information for specific patient populations. Clinical decisions should always be guided by the individual patient’s condition, the most recent product labeling, and institutional protocols.

Table

Table 3. Dosage Adjustments of Cholinesterase Inhibitors in Specific Patient Populations .

Adverse Effects

Cholinesterase inhibitors increase the overall availability of ACh. Thus, symptoms of parasympathetic nervous system overstimulation, such as increased hypermotility, hypersecretion, bradycardia, miosis, diarrhea, and hypotension, may occur.

A major concern when prescribing cholinesterase inhibitors or exposure to organophosphates is the potential for developing a cholinergic crisis, also known as SLUDGE syndrome.[31]

SLUDGE is a mnemonic that stands for:

• S: Salivation
• L: Lacrimation
• U: Urination
• D: Diaphoresis
• G: Gastrointestinal upset
• E: Emesis

Another commonly used mnemonic is DUMBBELLS, which also includes miosis and bronchospasm:

• D: Diaphoresis, diarrhea
• U: Urination (incontinence)
• M: Miosis (pinpoint pupils)
• B: Bradycardia
• B: Bronchospasm
• E: Emesis
• L: Lacrimation
• L: Lethargy and low blood pressure
• S: Salivation [32]

Temporary adverse effects when initiating patients on cholinesterase inhibitors include headaches, insomnia, and minor gastrointestinal issues. More concerning effects include lightheadedness, weakness, and weight loss. In some cases, prolonged muscle contraction may also be a presenting feature in patients exposed to cholinesterase inhibitors.[33][34]

Drug-Drug Interactions

Donepezil: Donepezil is highly protein-bound and exhibits weak in vitro inhibition of CYP3A4 and CYP2D6. Strong CYP3A4 and CYP2D6 inhibitors, such as ketoconazole and quinidine, can inhibit donepezil metabolism, with ketoconazole increasing its exposure. CYP inducers, such as phenytoin, carbamazepine, dexamethasone, rifampin, and phenobarbital, may increase donepezil clearance and reduce its efficacy.

Galantamine: Galantamine is metabolized via several pathways, with CYP2D6 and CYP3A4 being the principal contributors. Strong CYP3A4 inhibitors (eg, ketoconazole) increase systemic exposure. CYP2D6 inhibitors, such as fluoxetine, quinidine, and paroxetine, can reduce clearance and increase bioavailability. Cimetidine increases galantamine exposure, whereas ranitidine shows no significant effect. Coadministration with digoxin may increase the risk of bradyarrhythmia.

Benzgalantamine: Benzgalantamine shares the same interaction profile as galantamine, its active metabolite. The drug antagonizes anticholinergic drugs, potentially reducing their clinical effect. Additive cholinergic effects may occur when combined with cholinomimetics or other cholinesterase inhibitors. Synergistic effects are also expected if benzgalantamine is used concomitantly with succinylcholine and cholinergic agonists such as bethanechol.

Rivastigmine: Concomitant use with metoclopramide increases the risk of extrapyramidal reactions and should be avoided. Rivastigmine may enhance the effects of cholinomimetic drugs and may diminish the therapeutic response to anticholinergic medications, such as oxybutynin or tolterodine. Rivastigmine can also cause additive bradycardia when combined with beta-blockers; therefore, concurrent use with beta-blockers should be avoided in patients with bradycardia or a history of syncope.

Pyridostigmine: Atropine antagonizes the muscarinic effects of pyridostigmine toxicity or overdose and is used to counteract muscarinic symptoms such as salivation, sweating, and bradycardia. Drugs that interfere with neuromuscular transmission, including aminoglycosides, anesthetics, and antiarrhythmics, should be used cautiously or avoided, as they may worsen muscle weakness in patients with myasthenia gravis. Beta-blockers should be used cautiously in patients with hypertension or glaucoma, as pyridostigmine may worsen bradycardia. Concurrent use of anticholinesterases for glaucoma may produce additive effects, leading to vision problems due to increased cholinergic activity in the eye.[35]

Neostigmine: Neostigmine is primarily metabolized by hepatic microsomal enzymes; caution is advised when used with strong enzyme inducers or inhibitors. When administered postoperatively to reverse neuromuscular blockade, neostigmine may cause residual neuromuscular block.[36] 

Physostigmine: Physostigmine should be used with extreme caution with other cholinesterase inhibitors, including those prescribed for dementia, as concurrent therapy may increase the risk of cholinergic adverse effects. Physostigmine is contraindicated in cases of intoxication with depolarizing neuromuscular blockers, such as succinylcholine (suxamethonium), as it can increase the depolarizing block and worsen neuromuscular paralysis.

Contraindications

As cholinesterase inhibitors can enhance vagal tone by activating the parasympathetic nervous system, they should be used with caution in patients with bradycardia or cardiac conduction disorders, such as sick sinus syndrome, who are at increased risk of syncope and falls. Caution is also warranted in patients receiving antihypertensive therapy due to the potential for severe hypotension.[37]

Moreover, cholinesterase inhibitors are also contraindicated in patients with gastric ulcers due to the increased risk of gastrointestinal bleeding. Peritonitis or mechanical obstruction of the urinary or intestinal tracts typically contraindicates the use of cholinesterase inhibitors.

Administration is likewise contraindicated in patients with a history of allergy or hypersensitivity to cholinesterase inhibitors or their derivatives.[38]

Monitoring

The therapeutic index varies among different classes of cholinesterase inhibitors. Physostigmine, which has a short half-life and a narrow therapeutic index, is associated with adverse effects such as nausea, vomiting, stomach cramps, and diarrhea; therefore, it is not currently recommended for the treatment of dementia. Donepezil, which is used in treating Alzheimer disease, is well absorbed and relatively well tolerated, although higher dosages can produce adverse effects. The oral capsule formulation of rivastigmine can cause gastrointestinal upset; however, the development of a transdermal version improved tolerability in many studies. Both donepezil and rivastigmine are FDA-approved and associated with fewer adverse effects than older cholinesterase inhibitors. The safety and efficacy of newer generations of cholinesterase inhibitors, such as metrifonate, are currently under investigation. In cases where confirming the diagnosis is challenging, red blood cell cholinesterase activity can be measured from a blood sample.[39][40] 

Galantamine is indicated for the treatment of cognitive decline in mild-to-moderate Alzheimer disease. Galantamine is a potent allosteric potentiating ligand of human nicotinic ACh receptors, and it also acts as a weak, competitive, and reversible cholinesterase inhibitor throughout the body.

The American Society of Anesthesiologists recommends using quantitative neuromuscular monitoring in conjunction with clinical assessment to prevent residual neuromuscular blockade. The train-of-four ratio is used, and a value greater than 0.9 is advised before extubation. The adductor pollicis muscle is suggested for neuromuscular monitoring.[41] A recent study found no significant association between cholinesterase inhibitor use and QTc interval prolongation. However, additional studies are required, especially in high-risk patient populations.[42] 

Toxicity

Signs and Symptoms of Overdose

The potential toxicity of cholinesterase inhibitors stems from their mechanism of action, leading to excessive accumulation of acetylcholine. The clinical spectrum of toxicity varies among patients, which is also complicated by the type of cholinesterase inhibitor a patient is exposed to. SLUDGE syndrome, as described above, is the most recognized form of toxicity for cholinesterase inhibitors. Severe respiratory depression can also occur.

Increased ACh at neuromuscular junctions can also be a sign of toxicity and may result in involuntary movements such as muscle fibrillation, fasciculations, and paralysis. These findings should raise a strong suspicion of cholinesterase inhibitor overdose.[43]

Miosis is a common sign of cholinergic toxicity. Excess ACh causes contraction of the sphincter pupillae muscle that encompasses the iris. Miosis is considered one of the most sensitive indicators of exposure to cholinesterase-inhibiting aerosols, including organophosphates and pesticides.[44]

Management of Overdose

First-line treatments for suspected cholinesterase inhibitor toxicity include atropine, pralidoxime (2-PAM), and diazepam. Atropine competitively blocks muscarinic receptor sites, therefore reducing the binding of ACh. However, it does not counteract nicotinic effects such as muscle fasciculations and weakness; thus, ventilation or respiratory support may still be necessary.[45] 

2-PAM functions by reversing the binding of cholinesterase inhibitors to AChE. When administered concurrently, 2-PAM and atropine produce a synergistic effect.[46]

Seizures due to cholinesterase inhibitor toxicity are more apparent in pediatric patients and in adults exposed to nerve agents; therefore, requiring immediate management with diazepam. The American College of Medical Toxicology supports the use of atropine autoinjectors, atropine 1% sublingual, and glycopyrrolate administered IM, IV, or intraosseously as alternative countermeasures. Similarly, IM lorazepam may also be used as an alternative to diazepam.[47] 

Atropine may also be used for donepezil overdose, along with supportive measures. Because overdose management strategies continue to evolve, it is recommended to contact a Poison Control Center to obtain the most up-to-date guidance for managing drug overdose or toxicity.

Enhancing Healthcare Team Outcomes

Effective treatment of patients treated with cholinesterase inhibitors, particularly in cases of toxicity, requires a coordinated interprofessional approach. Because many patients with cholinesterase inhibitor toxicity initially present to the emergency department, triage nurses must be familiar with the associated symptoms, and affected patients often require prompt admission to a monitored setting. Early recognition and timely intervention are essential to improving clinical outcomes.

In cases of cholinesterase inhibitor toxicity, optimal care requires collaboration among nurses, laboratory technicians, pharmacists, physicians, and other healthcare professionals. Patients admitted under these circumstances require close monitoring by nursing staff and clinicians, along with timely laboratory evaluation, accurate assessment of symptoms, and anticipation of appropriate treatment steps. Pharmacists should be consulted regarding the use of atropine, pralidoxime, and benzodiazepines when cholinesterase inhibitor toxicity is suspected. Consultation with a toxicologist or intensivist is often necessary to achieve optimal clinical results, as many cases require advanced or interventional management during hospitalization.

For toxicity related to neostigmine, the anesthesiology team should be promptly notified. Respiratory therapists also play a vital role in treating patients who require mechanical ventilation or noninvasive respiratory support. Through comprehensive interprofessional coordination, patients experiencing cholinergic toxicity are more likely to achieve optimal clinical outcomes.

In addition to managing toxicity, cholinesterase inhibitor therapy for conditions such as dementia, Alzheimer disease, and myasthenia gravis often requires collaboration with a neurologist.[48] Given the clinical complexity of these patients, particularly those with advanced disease who may be unable to participate fully in their care, close communication among prescribing clinicians, nursing staff, and pharmacists is essential. This coordination supports appropriate drug selection, dosing, administration, and monitoring for adverse effects.

Interprofessional collaboration is also critical in cases of poisoning, as patients who receive prompt treatment generally have favorable outcomes, whereas delays in care are associated with increased morbidity. A retrospective cohort study using electronic health records and claims data evaluated prescribing patterns of cholinesterase inhibitors, including donepezil, rivastigmine, and galantamine. Researchers found that donepezil remained the most frequently prescribed agent across dementia subtypes, while galantamine use was comparatively limited, warranting further investigation.[49] Overall, an interprofessional team approach involving physicians, advanced practice providers, pharmacists, and nurses is essential for minimizing adverse effects and optimizing outcomes in patients receiving cholinesterase inhibitor therapy.

Review Questions

• Access free multiple choice questions on this topic.
• Comment on this article.

References

1.

Sheikh M, Ammar M. Efficacy of 5 and 10 mg donepezil in improving cognitive function in patients with dementia: a systematic review and meta-analysis. Front Neurosci. 2024;18:1398952. [PMC free article: PMC11298496] [PubMed: 39104606]

2.

Mori E, Ikeda M, Ohdake M. Donepezil for dementia with Lewy bodies: meta-analysis of multicentre, randomised, double-blind, placebo-controlled phase II, III, and, IV studies. Psychogeriatrics. 2024 May;24(3):589-596. [PMC free article: PMC11578031] [PubMed: 38439217]

3.

Stinton C, McKeith I, Taylor JP, Lafortune L, Mioshi E, Mak E, Cambridge V, Mason J, Thomas A, O'Brien JT. Pharmacological Management of Lewy Body Dementia: A Systematic Review and Meta-Analysis. Am J Psychiatry. 2015 Aug 01;172(8):731-42. [PubMed: 26085043]

4.

Colović MB, Krstić DZ, Lazarević-Pašti TD, Bondžić AM, Vasić VM. Acetylcholinesterase inhibitors: pharmacology and toxicology. Curr Neuropharmacol. 2013 May;11(3):315-35. [PMC free article: PMC3648782] [PubMed: 24179466]

5.

Ma SL, Tang NLS, Wat KHY, Tang JHY, Lau KH, Law CB, Chiu J, Tam CCW, Poon TK, Lin KL, Kng CPL, Kong HL, Chan TY, Chan WC, Lam LCW. Effect of CYP2D6 and CYP3A4 Genotypes on the Efficacy of Cholinesterase Inhibitors in Southern Chinese Patients With Alzheimer's Disease. Am J Alzheimers Dis Other Demen. 2019 Aug;34(5):302-307. [PMC free article: PMC10852420] [PubMed: 31064198]

6.

Lin YW, Truong D. Diffuse Lewy body disease. J Neurol Sci. 2019 Apr 15;399:144-150. [PubMed: 30807982]

7.

Meng YH, Wang PP, Song YX, Wang JH. Cholinesterase inhibitors and memantine for Parkinson's disease dementia and Lewy body dementia: A meta-analysis. Exp Ther Med. 2019 Mar;17(3):1611-1624. [PMC free article: PMC6364145] [PubMed: 30783428]

8.

Masuda M, Utsumi H, Tanaka S, Maeno A, Yamamoto M, Sugiyama K, Hirano T, Aizawa H. Treatment of Myasthenia Gravis With High-Dose Cholinesterase Inhibitors and Calcineurin Inhibitors Caused Spontaneous Muscle Cramps in Patients. Clin Neuropharmacol. 2018 Sep/Oct;41(5):164-170. [PubMed: 30130259]

9.

Shoja Shafti S, Azizi Khoei A. Effectiveness of rivastigmine on positive, negative, and cognitive symptoms of schizophrenia: a double-blind clinical trial. Ther Adv Psychopharmacol. 2016 Oct;6(5):308-316. [PMC free article: PMC5036138] [PubMed: 27721970]

10.

Reichert M, Willis F, Post S, Schneider M, Vilz T, Willis M, Hecker A. Pharmacologic prevention and therapy of postoperative paralytic ileus after gastrointestinal cancer surgery: systematic review and meta-analysis. Int J Surg. 2024 Jul 01;110(7):4329-4341. [PMC free article: PMC11254286] [PubMed: 38526522]

11.

Chen Q, Li N, Wu Y. Neostigmine for postoperative surgical urine retention: A systematic review and meta-analysis. Adv Clin Exp Med. 2024 May;33(5):435-444. [PubMed: 37665083]

12.

Ahmad J, Hasan MJ, Anam AM, Barua DK. Donepezil: an unusual therapy for acute diphenhydramine overdose. BMJ Case Rep. 2019 Mar 20;12(3) [PMC free article: PMC6453413] [PubMed: 30898954]

13.

Ostergaard D, Engbaek J, Viby-Mogensen J. Adverse reactions and interactions of the neuromuscular blocking drugs. Med Toxicol Adverse Drug Exp. 1989 Sep-Oct;4(5):351-68. [PubMed: 2682131]

14.

Gambardella MD, Wang Y, Pang J. The Selectivity of Butyrylcholinesterase Inhibitors Revisited. Molecules. 2025 Oct 27;30(21) [PMC free article: PMC12609153] [PubMed: 41226162]

15.

Howell M, Avidan AY, Foldvary-Schaefer N, Malkani RG, During EH, Roland JP, McCarter SJ, Zak RS, Carandang G, Kazmi U, Ramar K. Management of REM sleep behavior disorder: an American Academy of Sleep Medicine clinical practice guideline. J Clin Sleep Med. 2023 Apr 01;19(4):759-768. [PMC free article: PMC10071384] [PubMed: 36515157]

16.

Okamoto LE, Walsh E, Diedrich A, Shibao CA, Gamboa A, Black BK, Paranjape SY, Muldowney JA, Habermann R, Peltier A, Tarpara K, Biaggioni I. Clinical Correlates of Efficacy of Pyridostigmine in the Treatment of Orthostatic Hypotension. Hypertension. 2025 Mar;82(3):489-497. [PMC free article: PMC11839338] [PubMed: 39727053]

17.

Holder AC, Dylewski A, Brown JN. Pyridostigmine for the Management of Neurogenic Orthostatic Hypotension: A Systemic Review. J Geriatr Psychiatry Neurol. 2025 Mar;38(2):85-93. [PubMed: 39043171]

18.

Fortea J, Ferrer-Picón E. An overview of the rivastigmine 13.3 mg/24h transdermal patch as a treatment option for Alzheimer's disease. Expert Rev Neurother. 2025 Sep;25(9):1119-1129. [PubMed: 40600688]

19.

Oliveira C, Bagetta D, Cagide F, Teixeira J, Amorim R, Silva T, Garrido J, Remião F, Uriarte E, Oliveira PJ, Alcaro S, Ortuso F, Borges F. Benzoic acid-derived nitrones: A new class of potential acetylcholinesterase inhibitors and neuroprotective agents. Eur J Med Chem. 2019 Jul 15;174:116-129. [PubMed: 31029943]

20.

Wang P, Li H, Hassan MM, Guo Z, Zhang ZZ, Chen Q. Fabricating an Acetylcholinesterase Modulated UCNPs-Cu²⁺ Fluorescence Biosensor for Ultrasensitive Detection of Organophosphorus Pesticides-Diazinon in Food. J Agric Food Chem. 2019 Apr 10;67(14):4071-4079. [PubMed: 30888170]

21.

Bajgar J, Kassa J, Kucera T, Musilek K, Jun D, Kuca K. Some Possibilities to Study New Prophylactics against Nerve Agents. Mini Rev Med Chem. 2019;19(12):970-979. [PubMed: 30827238]

22.

Chou PS, Jhang KM, Huang LC, Wang WF, Yang YH. Skinfold thickness for rivastigmine patch application in Alzheimer's disease. Psychopharmacology (Berl). 2019 Apr;236(4):1255-1260. [PubMed: 30645680]

23.

Su J, Liu Y, Liu Y, Ren L. Long-term effectiveness of rivastigmine patch or capsule for mild-to-severe Alzheimer's disease: a meta-analysis. Expert Rev Neurother. 2015;15(9):1093-103. [PubMed: 26289489]

24.

Kurz A, Farlow M, Lefèvre G. Pharmacokinetics of a novel transdermal rivastigmine patch for the treatment of Alzheimer's disease: a review. Int J Clin Pract. 2009 May;63(5):799-805. [PMC free article: PMC2734925] [PubMed: 19392927]

25.

Drugs and Lactation Database (LactMed®) [Internet]. National Institute of Child Health and Human Development; Bethesda (MD): Dec 15, 2024. Physostigmine. [PubMed: 30000801]

26.

Drugs and Lactation Database (LactMed®) [Internet]. National Institute of Child Health and Human Development; Bethesda (MD): Dec 19, 2022. Pyridostigmine. [PubMed: 30000445]

27.

Drugs and Lactation Database (LactMed®) [Internet]. National Institute of Child Health and Human Development; Bethesda (MD): Feb 15, 2026. Neostigmine. [PubMed: 30000438]

28.

Boerner RM, Young DL, Gnagi SH, White DR, Halstead LA. Pyridostigmine for the Reversal of Severe Adverse Reactions to Botulinum Toxin in Children. J Pediatr. 2018 Mar;194:241-243. [PubMed: 29275924]

29.

O'Connell K, Ramdas S, Palace J. Management of Juvenile Myasthenia Gravis. Front Neurol. 2020;11:743. [PMC free article: PMC7393473] [PubMed: 32793107]

30.

By the 2023 American Geriatrics Society Beers Criteria® Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2023 Jul;71(7):2052-2081. [PMC free article: PMC12478568] [PubMed: 37139824]

31.

Ohbe H, Jo T, Matsui H, Fushimi K, Yasunaga H. Cholinergic Crisis Caused by Cholinesterase Inhibitors: a Retrospective Nationwide Database Study. J Med Toxicol. 2018 Sep;14(3):237-241. [PMC free article: PMC6097965] [PubMed: 29907949]

32.

Nguyen HH, Kidron A, Liu T, Nguyen N, Nguyen H, Vo A. Presentation and Treatment of cholinergic Crisis in the setting of Carbamate poisoning. Clin Case Rep. 2021 Apr;9(4):1887-1889. [PMC free article: PMC8077244] [PubMed: 33936608]

33.

Obara K, Ogawa T, Chino D, Tanaka Y. The Long-Lasting Enhancing Effect of Distigmine on Acetylcholine-Induced Contraction of Guinea Pig Detrusor Smooth Muscle Correlates with Its Anticholinesterase Activity. Biol Pharm Bull. 2017;40(7):1092-1100. [PubMed: 28674252]

34.

Inglis F. The tolerability and safety of cholinesterase inhibitors in the treatment of dementia. Int J Clin Pract Suppl. 2002 Jun;(127):45-63. [PubMed: 12139367]

35.

Remijn-Nelissen L, Verschuuren JJGM, Tannemaat MR. The effectiveness and side effects of pyridostigmine in the treatment of myasthenia gravis: a cross-sectional study. Neuromuscul Disord. 2022 Oct;32(10):790-799. [PubMed: 36184373]

36.

Luo J, Chen S, Min S, Peng L. Reevaluation and update on efficacy and safety of neostigmine for reversal of neuromuscular blockade. Ther Clin Risk Manag. 2018;14:2397-2406. [PMC free article: PMC6292224] [PubMed: 30573962]

37.

Gill SS, Anderson GM, Fischer HD, Bell CM, Li P, Normand SL, Rochon PA. Syncope and its consequences in patients with dementia receiving cholinesterase inhibitors: a population-based cohort study. Arch Intern Med. 2009 May 11;169(9):867-73. [PubMed: 19433698]

38.

Bonner LT, Peskind ER. Pharmacologic treatments of dementia. Med Clin North Am. 2002 May;86(3):657-74. [PubMed: 12171061]

39.

Mehta M, Adem A, Sabbagh M. New acetylcholinesterase inhibitors for Alzheimer's disease. Int J Alzheimers Dis. 2012;2012:728983. [PMC free article: PMC3246720] [PubMed: 22216416]

40.

Gupta S, Belle VS, Kumbarakeri Rajashekhar R, Jogi S, Prabhu RK. Correlation of Red Blood Cell Acetylcholinesterase Enzyme Activity with Various RBC Indices. Indian J Clin Biochem. 2018 Oct;33(4):445-449. [PMC free article: PMC6170242] [PubMed: 30319191]

41.

Thilen SR, Weigel WA, Todd MM, Dutton RP, Lien CA, Grant SA, Szokol JW, Eriksson LI, Yaster M, Grant MD, Agarkar M, Marbella AM, Blanck JF, Domino KB. 2023 American Society of Anesthesiologists Practice Guidelines for Monitoring and Antagonism of Neuromuscular Blockade: A Report by the American Society of Anesthesiologists Task Force on Neuromuscular Blockade. Anesthesiology. 2023 Jan 01;138(1):13-41. [PubMed: 36520073]

42.

Isotalo HK, Lehtovaara JK, Ekblad LL, Nuotio MS, Langén VLJ. Effects of Cholinesterase Inhibitor Medication on QTc Interval in Memory Clinic Patients. Ann Pharmacother. 2026 Jan;60(1):42-52. [PMC free article: PMC12696191] [PubMed: 40326082]

43.

Pope CN, Brimijoin S. Cholinesterases and the fine line between poison and remedy. Biochem Pharmacol. 2018 Jul;153:205-216. [PMC free article: PMC5959757] [PubMed: 29409903]

44.

Mattio TG, Richardson JS, Giacobini E. Effects of DFP on iridic metabolism and release of acetylcholine and on pupillary function in the rat. Neuropharmacology. 1984 Oct;23(10):1207-14. [PubMed: 6521855]

45.

Singh S, Batra YK, Singh SM, Wig N, Sharma BK. Is atropine alone sufficient in acute severe organophosphorus poisoning?: experience of a North West Indian Hospital. Int J Clin Pharmacol Ther. 1995 Nov;33(11):628-30. [PubMed: 8688989]

46.

Burillo-Putze G, Hoffman RS, Howland MA, Duenas-Laita A. Late administration of pralidoxime in organophosphate (fenitrothion) poisoning. Am J Emerg Med. 2004 Jul;22(4):327-8. [PubMed: 15258887]

47.

Stolbach A, Bebarta V, Beuhler M, Carstairs S, Nelson L, Wahl M, Wax PM, McKay C. ACMT Position Statement: Alternative or Contingency Countermeasures for Acetylcholinesterase Inhibiting Agents. J Med Toxicol. 2018 Sep;14(3):261-263. [PMC free article: PMC6097966] [PubMed: 29667118]

48.

Harish Bindignavile S. Myasthenia Gravis - An Updated Review. Int Ophthalmol Clin. 2026 Jan 01;66(1):55-61. [PubMed: 41429676]

49.

Heo RJ, Negida A, Barrett MJ, Chrenka EA, Bayram E, Kane JPM, Werner AM, Rossom RC, Wyman-Chick KA. Cholinesterase inhibitors for patients with dementia: Patterns of prescribing and disparities in treatment. J Alzheimers Dis. 2026 Feb;109(4):1917-1924. [PubMed: 41527747]

Disclosure: Ravneet Singh declares no relevant financial relationships with ineligible companies.

Disclosure: Preeti Patel declares no relevant financial relationships with ineligible companies.